{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T11:51:25Z","timestamp":1793793085713,"version":"4.6.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019832","name":"Galapagos NV","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019832","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess the effect of filgotinib, which preferentially inhibits Janus kinase 1 (JAK1), on MRI measures of structural change in the SI joint in patients with active AS in the TORTUGA trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adults with active AS and inadequate response\/intolerance to two or more NSAIDs were randomized 1:1 to filgotinib 200\u2009mg (n\u2009=\u200958) or placebo (n\u2009=\u200958) once daily for 12\u2009weeks. In this post hoc analysis, T1-weighted MRI scans of the SI joint were evaluated by two independent readers using Spondyloarthritis Research Consortium of Canada (SPARCC) Sacroiliac Joint Structural Score (SSS) definitions for erosion, backfill, fat metaplasia and ankylosis. Correlations between SPARCC SSS and improvement in clinical outcomes were also assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>MRI scans from 87 patients (48 filgotinib, 39 placebo) were evaluated. At baseline there were no notable differences between filgotinib and placebo for any MRI structural lesion types. From baseline to week 12, filgotinib was associated with a significant reduction in SI joint erosion score (P\u2009=\u20090.02) and an increase in backfill score (P\u2009=\u20090.005) vs placebo, with no significant between-group differences for ankylosis (P\u2009=\u20090.46) or fat metaplasia (P\u2009=\u20090.17). At week 12, the change in SPARCC MRI SI joint inflammation scores correlated positively with erosion scores but negatively with backfill scores.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The significant changes in MRI structural lesions induced by filgotinib in the SI joint by week 12 demonstrate that tissue repair can be observed very soon after starting treatment with a JAK1 preferential inhibitor. This could have prognostic implications for development of ankylosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov, http:\/\/clinicaltrials.gov, NCT03117270<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab543","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T11:57:05Z","timestamp":1628078225000},"page":"2063-2071","source":"Crossref","is-referenced-by-count":34,"title":["Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12\u2009weeks in patients with active ankylosing spondylitis (TORTUGA trial)"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-1755","authenticated-orcid":false,"given":"Walter P","family":"Maksymowych","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[{"name":"Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Landew\u00e9","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Amsterdam University Medical Center, Amsterdam and Zuyderland Medical Center, Heerlen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Barchuk","sequence":"additional","affiliation":[{"name":"Clinical Research, Gilead Sciences, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Research, Gilead Sciences, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Tasset","sequence":"additional","affiliation":[{"name":"Late Stage Development, Galapagos NV"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Gilles","sequence":"additional","affiliation":[{"name":"Biostatistics, LACO, Contracted by Galapagos NV, Mechelen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thijs","family":"Hendrikx","sequence":"additional","affiliation":[{"name":"Medical Affairs"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Besuyen","sequence":"additional","affiliation":[{"name":"Clinical Development, Galapagos BV, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"key":"2022050522164830200_keab543-B1","doi-asserted-by":"crossref","first-page":"vi4","DOI":"10.1093\/rheumatology\/key001","article-title":"Progress in our understanding of the pathogenesis of ankylosing spondylitis","volume":"57","author":"Simone","year":"2018","journal-title":"Rheumatology (Oxford"},{"key":"2022050522164830200_keab543-B2","doi-asserted-by":"crossref","first-page":"vi23","DOI":"10.1093\/rheumatology\/key152","article-title":"Therapies in ankylosing spondylitis\u2014from clinical trials to clinical practice","volume":"57","author":"Tahir","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2022050522164830200_keab543-B3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/2040622317743486","article-title":"New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice","volume":"9","author":"Dubash","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"2022050522164830200_keab543-B4","first-page":"889","article-title":"One year in review 2018: axial spondyloarthritis","volume":"37","author":"Carli","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2022050522164830200_keab543-B5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11926-019-0856-3","article-title":"The pathogenesis of ankylosing spondylitis: an update","volume":"21","author":"Pedersen","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"2022050522164830200_keab543-B6","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.berh.2018.10.009","article-title":"Imaging in axial spondyloarthritis: changing concepts and thresholds","volume":"32","author":"Weber","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2022050522164830200_keab543-B7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13075-017-1342-9","article-title":"MRI evidence of structural changes in the sacroiliac joints of patients with non-radiographic axial spondyloarthritis even in the absence of MRI inflammation","volume":"19","author":"Maksymowych","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2022050522164830200_keab543-B8","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00256-011-1204-5","article-title":"The impact of MRI on the clinical management of inflammatory arthritides","volume":"40","author":"Weber","year":"2011","journal-title":"Skeletal Radiol"},{"key":"2022050522164830200_keab543-B9","first-page":"1953","article-title":"Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study","volume":"26","author":"Oostveen","year":"1999","journal-title":"J Rheumatol"},{"key":"2022050522164830200_keab543-B10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40744-019-0146-6","article-title":"Non-radiographic axial spondyloarthritis (nr-axSpA): advances in classification, imaging and therapy","volume":"6","author":"Robinson","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2022050522164830200_keab543-B11","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2019-215707","article-title":"Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts","volume":"78","author":"Boel","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022050522164830200_keab543-B12","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2019-215589","article-title":"MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group","volume":"78","author":"Maksymowych","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022050522164830200_keab543-B13","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1002\/art.38792","article-title":"Fat metaplasia and backfill are key intermediaries in the development of sacroiliac joint ankylosis in patients with ankylosing spondylitis","volume":"66","author":"Maksymowych","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2022050522164830200_keab543-B14","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1136\/annrheumdis-2015-208642","article-title":"Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group","volume":"75","author":"Lambert","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022050522164830200_keab543-B15","doi-asserted-by":"crossref","first-page":"e000918","DOI":"10.1136\/rmdopen-2019-000918","article-title":"Evaluation of the performances of \u2018typical\u2019 imaging abnormalities of axial spondyloarthritis: results of the cross-sectional ILOS-DESIR study","volume":"5","author":"Molto","year":"2019","journal-title":"RMD Open"},{"key":"2022050522164830200_keab543-B16","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022050522164830200_keab543-B17","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/art.39434","article-title":"Course of magnetic resonance imaging-detected inflammation and structural lesions in the sacroiliac joints of patients in the randomized, double-blind, placebo-controlled Danish multicenter study of adalimumab in spondyloarthritis, as assessed by the Berlin and Spondyloarthritis Research Consortium of Canada Methods","volume":"68","author":"Pedersen","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022050522164830200_keab543-B18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/annrheumdis-2017-211605","article-title":"Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis","volume":"77","author":"Maksymowych","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022050522164830200_keab543-B19","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.12688\/f1000research.14956.1","article-title":"Recent advances in ankylosing spondylitis: understanding the disease and management","volume":"7","author":"Garcia-Montoya","year":"2018","journal-title":"F1000Res"},{"key":"2022050522164830200_keab543-B20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/rheumatology\/key070","article-title":"The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis","volume":"58","author":"Veale","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2022050522164830200_keab543-B21","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"key":"2022050522164830200_keab543-B22","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022050522164830200_keab543-B23","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"2022050522164830200_keab543-B24","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"2022050522164830200_keab543-B25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3899\/jrheum.140519","article-title":"Development and preliminary validation of the spondyloarthritis research consortium of Canada magnetic resonance imaging sacroiliac joint structural score","volume":"42","author":"Maksymowych","year":"2015","journal-title":"J Rheumatol"},{"key":"2022050522164830200_keab543-B26","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/art.21337","article-title":"Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis","volume":"53","author":"Maksymowych","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2022050522164830200_keab543-B27","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.21445","article-title":"Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis","volume":"53","author":"Maksymowych","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2022050522164830200_keab543-B28","first-page":"abstract 586","article-title":"Validation of online calibration modules for the Spondyloarthritis Research Consortium of Canada MRI scores based on real-time experiential learning","volume":"69(Suppl 10","author":"Maksymowych","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022050522164830200_keab543-B29","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3899\/jrheum.140806","article-title":"Metric properties of the SPARCC score of the sacroiliac joints\u2014data from baseline, 3-month, and 12-month followup in the SPACE cohort","volume":"42","author":"van den Berg","year":"2015","journal-title":"J Rheumatol"},{"key":"2022050522164830200_keab543-B30","doi-asserted-by":"crossref","first-page":"e000399","DOI":"10.1136\/rmdopen-2016-000399","article-title":"Fat metaplasia on MRI of the sacroiliac joints increases the propensity for disease progression in the spine of patients with spondyloarthritis","volume":"3","author":"Maksymowych","year":"2017","journal-title":"RMD Open"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab543\/40426659\/keab543.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/5\/2063\/43562300\/keab543.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/5\/2063\/43562300\/keab543.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T22:27:43Z","timestamp":1651789663000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/5\/2063\/6342426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,8,5]]},"published-print":{"date-parts":[[2022,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab543","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2021,8,5]]}}}